Century Therapeutics (NASDAQ:IPSC) Rating Lowered to “Sell” at Wall Street Zen

Century Therapeutics (NASDAQ:IPSC) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Century Therapeutics in a research report on Saturday, September 27th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $3.75.

Century Therapeutics Trading Up 3.2%

NASDAQ:IPSC opened at $0.51 on Friday. The company has a market cap of $44.34 million, a price-to-earnings ratio of -1.77 and a beta of 1.78. Century Therapeutics has a twelve month low of $0.34 and a twelve month high of $1.83. The stock has a fifty day simple moving average of $0.52 and a 200-day simple moving average of $0.54.

Century Therapeutics (NASDAQ:IPSC) last issued its earnings results on Thursday, August 14th. The company reported ($0.38) EPS for the quarter, hitting analysts’ consensus estimates of ($0.38). Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 11.53%. As a group, equities research analysts predict that Century Therapeutics will post -1.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Jane Street Group LLC purchased a new position in shares of Century Therapeutics in the second quarter worth about $248,000. Acadian Asset Management LLC increased its holdings in Century Therapeutics by 101.2% in the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock worth $133,000 after buying an additional 142,953 shares during the period. Goldman Sachs Group Inc. raised its position in Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock worth $86,000 after buying an additional 38,052 shares during the last quarter. Squarepoint Ops LLC lifted its stake in Century Therapeutics by 56.0% during the 4th quarter. Squarepoint Ops LLC now owns 164,871 shares of the company’s stock valued at $167,000 after acquiring an additional 59,174 shares during the period. Finally, Nuveen LLC purchased a new stake in shares of Century Therapeutics in the 1st quarter valued at $75,000. 50.20% of the stock is owned by institutional investors and hedge funds.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.